Chronic Lymphocytic Leukemia

An overview of assessing risk of disease recurrence, steps taken to minimize recurrence, and when to consider second-line treatment for patients with CLL.

An expert on CLL reviews recent data updates from studies of BTK inhibitors in the frontline setting.

John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.

An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.

Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.

The phase 3 MAJIC study is underway to compare 2 frontline regimens for patients with chronic lymphocytic leukemia.

An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.

An expert hematologist-oncologist discusses the patient case and risk stratification for patients with newly diagnosed CLL.

According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.

Carolyn Owen, MD, discusses minimal residual disease as an area of research in the chronic lymphocytic leukemia space.

John Allan, MD, presents the case of a 72-year-old woman with newly diagnosed chronic lymphocytic leukemia and shares his initial impressions.

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Acquired resistance to BTK inhibitors is a new and growing challenge in the treatment of CLL and dual resistance to BTK and BCL2 is occurring in more patients, according to Lindsey Roeker, MD.

The triplet regimen acalabrutinib, venetoclax, and obinutuzumab in the frontline chronic lymphocytic leukemia setting was highly active and well tolerated demonstrating durable responses.

Jennifer R. Brown, MD, PhD, discusses what potential advancements are bringing excitement into the chronic lymphocytic leukemia space.

Jennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib.

An interim analysis of the phase 3 ALPINE study showed stronger results for patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma on the next generation BTK inhibitor zanubrutinib than standard of care ibrutinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, John N. Allan, MD, discussed the data supporting the use of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.

Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia. .

Jennifer R. Brown, MD, PhD, discusses the mechanism of action of zanubrutinib and how it differs from other Bruton’s tyrosine kinase inhibitors.

Topline results from the phase 2 TRANSCEND CLL 004 trial hint that lisocabtagene maraleucel may be active in relapsed or refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Carolyn Owen, MD, discussed findings from the GLOW study of elderly/unfit patients with chronic lymphocytic leukemia that were presented at SOHO 2022.

Zanubrutinib has been granted FDA approval for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Alexey Danilov, MD, PhD, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia.

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.

Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.

In an interview with Targeted Oncology, Thomas Kipps, MD, PhD, explained the new treatment options and challenges being faced in the chronic lymphocytic leukemia space.